Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
European Journal of Cancer (Oxford, England : 1990)|June 21, 2017
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)Alfredo Carrato, Albert Abad, Bartomeu Massuti, et al.
British Journal of Cancer|August 1, 2019
A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patientsElena Elez, Carles Pericay, Manuel Valladares-Ayerbes, et al.
Journal of Geriatric Oncology|June 26, 2020
First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL studyJosé Carlos Méndez Méndez, Mercedes Salgado Fernández, Juan de la Cámara Gómez, et al.
BMC Cancer|April 21, 2025
Associations of blood RNA biomarkers and circulating tumour cells in patients with previously untreated metastatic colorectal cancerManuel Valladares-Ayerbes, Marta Toledano-Fonseca, Begoña Graña, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 7, 2021
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)Manuel Benavides, Auxiliadora Gómez-España, Pilar García-Alfonso, et al.
Clinical Colorectal Cancer|March 17, 2012
Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive TumorsManuel Benavides, Carles Pericay, Manuel Valladares-Ayerbes, et al.
Cancer Chemotherapy and Pharmacology|January 16, 2021
Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX studyJaime Feliu, Mónica Jorge Fernández, Teresa Macarulla, et al.
Drugs & Aging|February 22, 2021
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled AnalysisPilar García-Alfonso, Eduardo Díaz-Rubio, Albert Abad, et al.
Molecular Cancer Therapeutics|June 20, 2017
Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal CancerCristina Santos, Daniel Azuara, Rocio Garcia-Carbonero, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2022
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)Guillem Argilés, Nuria Mulet, Manuel Valladares-Ayerbes, et al.
Pageof 7